{"name":"MiMedx Group","slug":"mimedx","ticker":"MDXG","exchange":"NASDAQ","domain":"mimedx.com","description":"MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applica","hq":"Marietta, GA","founded":0,"employees":"808","ceo":"Joseph H. Capper","sector":"Regenerative Medicine / Wound Care","stockPrice":4.05,"stockChange":0.19,"stockChangePercent":4.92,"marketCap":"$602M","metrics":{"revenue":418630000,"revenueGrowth":27.1,"grossMargin":82.6,"rdSpend":15097000,"netIncome":48578000,"cash":166120992,"dividendYield":0,"peRatio":12.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Micronized dHACM","genericName":"Micronized dHACM","slug":"micronized-dhacm","indication":"Diabetic foot ulcers","status":"phase_3"}]}],"pipeline":[{"name":"Micronized dHACM","genericName":"Micronized dHACM","slug":"micronized-dhacm","phase":"phase_3","mechanism":"Micronized dehydrated human amnion/chorion membrane (dHACM) provides a biologic scaffold that promotes tissue regeneration and wound healing through growth factors and extracellular matrix components.","indications":["Diabetic foot ulcers","Chronic wounds","Surgical wounds"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"MiMedx Group Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"MiMedx Group reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $1.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"MiMedx Group Announces Agreement to Sell EpiFix and EpiCel Assets to Smith & Nephew","summary":"MiMedx Group announced an agreement to sell its EpiFix and EpiCel assets to Smith & Nephew, a global medical technology company.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"regulatory","headline":"MiMedx Group Receives FDA Clearance for AmnioFix","summary":"MiMedx Group received FDA clearance for its AmnioFix product, a regenerative medicine for the treatment of chronic wounds.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"earnings","source":"simplywall.st","summary":"MiMedx Group (MDXG) Revenue Jump To US$118.1 Million Tests Slow Growth Narrative - simplywall.st","headline":"MiMedx Group (MDXG) Revenue Jump To US$118.1 Million Tests Slow Growth Narrative","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxQVm8zMGd0cHY3Zk5BWEdDT1JIVlMtZ29fVTVPeFh4bC1CV3M0dGFsQlhOUGJ1dnM0NFUyX040R1hSSHp3TVBIeFhOUjc0aHRmektNTUZEQW1qNjk5TVg1NHZDMDBMWVRUWWl0N0JsT0gwZkg4bzZXLVJmYy1sSDZiMUUtUE5TOUJQc2JSX1pNVDRDeVNCMjR1bTIxLWJJNXRwV3ZWdkt6NUpWYWpHRGZDZWFsZ1hkUzE1bEhaVUFTSGFQYnFEOTdra3NOMnlWNE5GZzNDTEtTX1k2ZDEyZU00RkRQQjg5dF9iQUhISzdYVHotbjhYRUhoenVTQm5PNmh0?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: MiMedx Group (MDXG), Ufp Technologies (UFPT) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: MiMedx Group (MDXG), Ufp Technologies (UFPT)","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"earnings","source":"simplywall.st","summary":"Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings - simplywall.st","headline":"Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-21","type":"pipeline","source":"simplywall.st","summary":"MiMedx (MDXG): Fresh Clinical Evidence Spurs a Closer Look at the Stock’s Valuation and Long-Term Upside Potential - simplywall.st","headline":"MiMedx (MDXG): Fresh Clinical Evidence Spurs a Closer Look at the Stock’s Valuation and Long-Term Upside Potential","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-15","type":"pipeline","source":"simplywall.st","summary":"Is MiMedx Group, Inc.'s (NASDAQ:MDXG) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st","headline":"Is MiMedx Group, Inc.'s (NASDAQ:MDXG) Recent Stock Performance Tethered To Its Strong Fundamentals?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPaFl3VnZsZWxhRXBKLXRrZmVMbE8xZmZoMnJuZmItS2VNcEk4cVpvZ2JvNWpUN18wVEE2WTlYQTBDRUlNVkFUTExtTUFWXzk1bFc1R2ctakdiVHJVUlRfcmpjV2h0cUI4UDlfei15M2czbG5uOTlpVVlnck1Ua2d0dDVITkVFNDZnV0JnYmo0c01mc3d6cTRwX3J0Q3hGTGtWV25fT29LUERVdFhrb21ZQmJPZVBOaWJHaDhxSVppUWdEMldjQThRRWVRVmdoNS05bEpPQUVFeVBBRjdISXk40gHkAUFVX3lxTFBwQ1dZZkk0Q3JGWXRsYXd5UzZuN3hiWmVFVkdENnZocmE3cjhpZVV3NDBDa1hHN29EcGZsYVhGeVBoZUllb19ycGwyLXBsM2poa0g4OFp3UHdicVRmYjhLcmUybENxdFNKSVhpWXJrOU5OTUdhbHNvdFRFVDZYUEN4a0NfTy1KZmtrQlUwQ3ROc1hKUVVHWFpobVFFNHB5bFFoNVpTRUNSc19MSnBCeXV4eU5nVlJUcDF6ZmQyVDJydHkzcE9qeDdtZU1zX2pJbG04bmRqdzlEbHpwS2huR0VuZXVBZg?oc=5","date":"2025-11-13","type":"pipeline","source":"simplywall.st","summary":"Chief Commercial Officer Of MiMedx Group Sold 71% Of Their Shares - simplywall.st","headline":"Chief Commercial Officer Of MiMedx Group Sold 71% Of Their Shares","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-06","type":"earnings","source":"simplywall.st","summary":"MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture - simplywall.st","headline":"MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNQTdtMnJJUXEzYk5yQlZ4OER5cVFtUEwwUUlkX1prV2dhejZqd0ZzQld2Z3BVOWVXTE9xZUt1d05VU1hDTlM3Qk55MjZDZlAwX2hubDF0ZVBrc282bi0wVUlqY2UxZ3R0RXMzMUJ5ZHg3LXRKNlVOcGxld2lHMElxSnQxc2pIV095RG50bG9n?oc=5","date":"2025-11-04","type":"pipeline","source":"Seeking Alpha","summary":"MiMedx: Breakout Setup Into A Policy Overhaul (NASDAQ:MDXG) - Seeking Alpha","headline":"MiMedx: Breakout Setup Into A Policy Overhaul (NASDAQ:MDXG)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-30","type":"pipeline","source":"simplywall.st","summary":"Institutional investors are MiMedx Group, Inc.'s (NASDAQ:MDXG) biggest bettors and were rewarded after last week's US$70m market cap gain - simplywall.st","headline":"Institutional investors are MiMedx Group, Inc.'s (NASDAQ:MDXG) biggest bettors and were rewarded after last week's US$70","sentiment":"neutral"},{"date":"2025-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-29","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-09-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Smith & Nephew","Organogenesis","Integra LifeSciences"],"therapeuticFocus":["Regenerative Medicine","Wound Care"],"financials":{"source":"sec_edgar","revenue":418630000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":418630000,"period":"2025-12-31"},{"value":348879000,"period":"2024-12-31"},{"value":348879000,"period":"2024-12-31"},{"value":321477000,"period":"2023-12-31"},{"value":321477000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15097000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":48578000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":342653000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.05,"previousClose":3.86,"fiftyTwoWeekHigh":7.99,"fiftyTwoWeekLow":3.77,"fiftyTwoWeekRange":"3.77 - 7.99","fiftyDayAverage":4.72,"twoHundredDayAverage":6.3,"beta":1.65,"enterpriseValue":429878016,"forwardPE":15.7,"priceToBook":2.34,"priceToSales":1.44,"enterpriseToRevenue":1.03,"enterpriseToEbitda":5.46,"pegRatio":0,"ebitda":78768000,"ebitdaMargin":18.8,"freeCashflow":63337000,"operatingCashflow":74003000,"totalDebt":22532000,"debtToEquity":8.8,"currentRatio":4.32,"returnOnAssets":13.2,"returnOnEquity":21.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":9.67,"targetHighPrice":10,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.3,"institutionHeldPercent":73.2,"sharesOutstanding":148566586,"floatShares":117608281,"sharesShort":6179889,"shortRatio":6.84,"shortPercentOfFloat":4.2,"epsTrailing":0.32,"epsForward":0.26,"revenuePerShare":2.83,"bookValue":1.73,"officers":[{"age":61,"name":"Mr. Joseph H. Capper","title":"CEO & Director"},{"age":59,"name":"Mr. Douglas C. Rice CPA","title":"Chief Financial Officer"},{"age":56,"name":"Ms. Ricci S. Whitlow","title":"Executive VP & COO"},{"age":51,"name":"Mr. William F. Hulse IV","title":"General Counsel & Chief Administrative Officer"},{"age":58,"name":"Ms. Kimberly  Maersk-Moller","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. Matthew M. Notarianni","title":"Head of Investor Relations"},{"age":59,"name":"Mr. Mark P. Graves","title":"Senior VP & Chief Compliance Officer"},{"age":null,"name":"Ms. Hilary  Dixon","title":"Vice President of Investor Relations & Corporate Strategic Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.mimedx.com","phone":"770 651 9100"}}